HCKH - PI Jan-Eric Turner - Hamburg Center for Kidney Health

Team

Jan-Eric Turner

Jan-Eric Turner

Mission Statement

“Establishing innate and innate-like lymphocytes as therapeutic targets in immune-mediated kidney diseases”

— Jan-Eric Turner, MD

Team Members

PhD Student

Lena Henneken

This email address is being protected from spambots. You need JavaScript enabled to view it.

Technician

Virginia Adamiak

This email address is being protected from spambots. You need JavaScript enabled to view it.

MD Student

Nick Rosenkranz

Research

Zoom

©Jan-Eric Turner

Lymphocytes of the innate and adaptive immune system are central regulators of the immune response in homeostasis and immune-mediated diseases. Recent studies have shown that specialized populations of innate lymphocytes and “innate-like” T cells that display features of both innate and adaptive immunity reside in the kidney where they contribute to production of cytokines and regulation of the local immune response. The contribution of these innate and innate-like lymphocyte populations to kidney injury and repair in immune-mediated renal diseases is still incompletely understood.

In the lab we use preclinical models of glomerulonephritis to study the function of kidney-resident innate and innate-like lymphocyte populations in kidney inflammation. These functional studies are complemented by a systems biology approach in which we perform high dimensional analysis of the molecular interactions of innate and innate-like lymphocytes with renal parenchymal cells in the healthy human kidney and in patients with glomerulonephritis.

Our studies are aimed at elucidating the role of innate and innate-like lymphocyte subsets in the renal immune response with a special focus on how these cells can be employed for targeted treatment approaches in patients with immune-mediated kidney diseases.

Jan-Eric Turner, MD

Principle Investigator

III. Department of Medicine & Hamburg Center for Translational Medicine, University Medical Center Hamburg-Eppendorf (UKE)
Martinistr. 52
20246 Hamburg, Germany

This email address is being protected from spambots. You need JavaScript enabled to view it.

CV

Current Position

since 2015	Principle Investigator “Innate Immune Regulation” Group, III. Department of Medicine, UKE
2020 - 2023	Managing Consultant, III. Department of Medicine, UKE
2016 - 2023	Consultant (Nephrology), III. Department of Medicine, UKE

University Training

1998 - 2005

Study of Medicine, Georg-August-Universität Göttingen, Germany

Academic qualifications

2023	Professorship, University of Hamburg
2016 - 2020	Habilitation and Venia Legendi for Internal Medicine and Nephrology, University of Hamburg
2015 - 2021	Principle Investigator of the Emmy-Noether-Research Group “Innate Lymphoid Cells in Renal Inflammation”, UKE
2011 - 2013	Postdoctoral Research Fellow, MRC National Institute for Medical Research, London, UK (Head: Dr. Brigitta Stockinger)
2009 - 2012	Co Principle Investigator, Clinical Research Unit 228, UKE
2006 - 2011	Clinician Scientist, III. Department of Medicine, UKE
2001 - 2006	MD Thesis, European Neuroscience Institute Göttingen, Germany

Previous professional career

Clinical postgraduate education:

2021	Additional Training in Immunology (certified by the Chamber of Physicians Hamburg)
2014	Clinical Specialisation in Internal Medicine and Nephrology (certified by the Chamber of Physicians Hamburg)

Scientific postgraduate education:

2011 - 2013	Postdoctoral Research Fellow, MRC National Institute for Medical Research, London, UK (Head: Dr. Brigitta Stockinger)
2006 - 2011	Postdoctoral Research Fellow, III. Department of Medicine, UKE

Selected awards and honors

2018 - 2020	Hans U. Zollinger Award for Immunologial Research in Nephrology, German Society of Nephrology
2015 - 2021	Emmy Noether Programme of the German Research Foundation
2013	Walter Hörl Fellowship of the German Kidney Foundation
2011 - 2013	Research Fellowship of the German Research Foundation

Selected publications

1.	Mucosal-associated invariant T cells contribute to suppression of inflammatory myeloid cells in immune-mediated kidney disease. Gnirck AC, Philipp MS, Waterhölter A, Wunderlich M, Shaikh N, Adamiak V, Henneken L, Kautz T, Xiong T, Klaus D, Tomczyk P, Al-Bahra MM, Menche D, Walkenhorst M, Lantz O, Willing A, Friese MA, Huber TB, Krebs CF, Panzer U, Kurts C, Turner JE. Nat Commun. 2023 Nov 15;14(1):7372.
2.	Retinoic acid drives intestine-specific adaptation of effector ILC2s originating from distant sites. Shaikh N, Waterhölter A, Gnirck AC, Becker M, Adamiak V, Henneken L, Wunderlich M, Hartmann W, Linnemann L, Huber TB, Krebs CF, Panzer U, Locksley RM, Wilhelm C, Breloer M, Turner JE. J Exp Med. 2023 Dec 4;220(12):e20221015.
3.	MAIT cells in immune-mediated tissue injury and repair. Waterhölter A, Wunderlich M, Turner JE. Eur J Immunol. 2023 Dec;53(12):e2350483.
4.	Conventional NK cells and ILC1s do not influence pathogenesis of experimental glomerulonephritis. Rickassel C, Gnirck AC, Shaikh N, Adamiak V, Waterhölter A, Tanriver Y, Neumann V, Huber TB, Gasteiger G, Panzer U, Turner JE. J Immunol. 2022 Apr 1;208(7):1585-1594.
5.	Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients. Zhao Y, Kilian C , Turner JE, Bosurgi L, Roedl K, Bartsch P, Gnirck AC, Cortesi F, Schultheiß C, Hellmig M, Enk LUB, Hausmann F, Borchers A, Wong MN, Paust HJ, Siracusa F, Scheibel N, Herrmann M, Rosati E, Bacher P, Kylies D, Jarczak D, Lütgehetmann D, Pfefferle S, Steurer S, Schulze-zur-Wiesch J, Puelles VG, Sperhake JP, Addo MM, Lohse AW, Binder M, Huber S, Huber TB, Kluge S, Bonn S, Panzer U, Gagliani N, Krebs CF. Sci Immunol.* 2021 Feb 23;6(56):eabf6692. *contributed equally.
6.	Interleukin-9 protects from early podocyte injury and progressive glomerulosclerosis in Adriamycin-induced nephropathy. Xiong T, Attar M, Gnirck AC, Wunderlich M, Becker M, Rickassel C, Puelles VG, Meyer-Schwesinger C, Wiech T, Nies JF, Divivier M, Fuchs T, Schulze Zur Wiesch J, Taipaleenmäki H, Hoxha E, Wirtz S, Huber TB, Panzer U, Turner JE. Kidney Int. 2020 Sep;98(3):615-629.
7.	IL-33-mediated expansion of type 2 Innate Lymphoid Cells protects from progressive glomerulosclerosis Riedel JH, Becker M, Kopp K, Düster M, Brix SR, Meyer-Schwesinger C, Kluth LA, Gnirck AC, Attar M, Krohn S, Fehse B, Stahl RA, Panzer U, Turner JE. J Am Soc Nephrol. 2017 Jul;28(7):2068-2080.
8.	Autoimmune Renal Disease Is Exacerbated by S1P-Receptor-1-Dependent Intestinal Th17 Cell Migration to the Kidney Krebs CF, Paust HJ, Krohn S, Koyro T, Brix SR, Riedel JH, Bartsch P, Wiech T, Meyer-Schwesinger C, Huang J, Fischer N, Busch P, Mittrucker HW, Steinhoff U, Stockinger B, Perez LG, Wenzel UO, Janneck M, Steinmetz OM, Gagliani N, Stahl RA, Huber S, Turner JE, Panzer U. Immunity. 2016 Nov 15;45(5):1078-1092.
9.	IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation Turner JE, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld JC, Panzer U, Helmby H, Stockinger B. J Exp Med. 2013 Dec 16;210(13):2951-65.
10.	Plasticity of TH17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses Hirota K, Turner JE, Villa M, Duarte JH, Demengeot J, Steinmetz OM, Stockinger B. Nat Immunol. 2013 Apr;14(4):372-9.